Comparative Pharmacology
Head-to-head clinical analysis: BENZNIDAZOLE versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZNIDAZOLE versus SATRIC.
BENZNIDAZOLE vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benznidazole is a nitroimidazole derivative that exerts trypanocidal activity against Trypanosoma cruzi. Its mechanism involves the reduction of the nitro group by a nitroreductase enzyme in the parasite, leading to the generation of toxic metabolites that damage parasite DNA and other cellular components.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
5-7 mg/kg/day orally divided into two daily doses for 60 days. Maximum daily dose: 300 mg.
No standard dosing information available for SATRIC.
None Documented
None Documented
Clinical Note
moderateBenznidazole + Leflunomide
"The risk or severity of adverse effects can be increased when Benznidazole is combined with Leflunomide."
Clinical Note
moderateBenznidazole + Fingolimod
"Benznidazole may increase the immunosuppressive activities of Fingolimod."
Clinical Note
moderateBenznidazole + Tofacitinib
"Benznidazole may increase the immunosuppressive activities of Tofacitinib."
Clinical Note
moderatePimecrolimus + Benznidazole
Terminal elimination half-life is approximately 12 hours; may be prolonged in hepatic impairment.
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Primarily renal excretion of metabolites; <5% unchanged drug. Approximately 20% in feces.
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category C
Category C
Antiprotozoal
Antiprotozoal, Antibiotic
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benznidazole."